Observational studyCancer reports (Hoboken, N.J.)2022

Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy.

Cristina Julian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.